19 Jul New Target To Treat Itch Identified
MedicalResearch.com Interview with:
Mark Hoon, PhD
Senior Investigator,Molecular Genetics Unit
NIH NIDCR, Bethesda, MD
MedicalResearch.com: What is the background for this study?
Response: Itch is a condition that at some point effects all people. For most of us itch is not a major problem, but for some people with certain chronic conditions it severely effects their quality of life.
Examples of diseases which cause chronic itch are atopic dermatitis, psoriasis, and renal failure. However, current therapies for chronic itch are mainly ineffective and there is a unmet clinical need.
MedicalResearch.com: What are the main findings?
Response: The main finding was that the receptor Npr1 is a feasible target for inhibition of itch.
MedicalResearch.com: What should readers take away from your report?
Response: The take away message is that, there new ways to treat itch are being actively investigated and these will likely, in the future, lead to novel therapies.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: We would recommend searching for better antagonist of Npr1 which have improved pharmacodynamics compared with the compounds we discovered in this study.
NIH has a patent pending his work.
Hans Jürgen Solinski, Patricia Dranchak, Erin Oliphant, Xinglong Gu, Thomas W. Earnest, John Braisted, James Inglese, Mark A. Hoon. Inhibition of natriuretic peptide receptor 1 reduces itch in mice. Science Translational Medicine, 2019; 11 (500): eaav5464 DOI: 10.1126/scitranslmed.aav5464
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.